Treatment of acute non lymphocytic leukemia. Results of a prospective trial of daunorubicin, arabinosylcytosine and 6-thioguanine (DAT) versus DAT plus vindesine and etoposide.

Giuseppe Bandini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), L Mangoni(University of Bologna), Benedetto Comotti(University of Bologna), Michele Baccarani(University of Bologna), Enrica Morra(University of Bologna), R Battista(University of Bologna), G Scapoli(University of Bologna), Fabiana Leoni(University of Bologna), G Todeschini(University of Bologna), Giovanna Cavazzini(University of Padua)
PubMed
February 9, 1988
Cited by 11

Related Papers

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
|Blood|2011|497
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
|Blood|2011|402
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
|Blood|2013|391
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
|Journal of Clinical Oncology|2007|374